New functions for the matrix metalloproteinases in cancer progression

[1]  R. Suzuki,et al.  Experimental metastasis is suppressed in MMP-9-deficient mice , 1999, Clinical & Experimental Metastasis.

[2]  J. Foidart,et al.  Gelatinase A expression and localization in human breast cancers. An in situ hybridization study and immunohistochemical detection using confocal microscopy , 2004, Virchows Archiv.

[3]  B. Fingleton,et al.  Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.

[4]  A. Strongin,et al.  Processing of Integrin αv Subunit by Membrane Type 1 Matrix Metalloproteinase Stimulates Migration of Breast Carcinoma Cells on Vitronectin and Enhances Tyrosine Phosphorylation of Focal Adhesion Kinase* , 2002, The Journal of Biological Chemistry.

[5]  I. Stamenkovic,et al.  CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. , 2002, Genes & development.

[6]  R. Ala-aho,et al.  Expression of collagenase‐3 (MMP‐13) enhances invasion of human fibrosarcoma HT‐1080 cells , 2002, International journal of cancer.

[7]  C. Kahn,et al.  Tumstatin, an Endothelial Cell-Specific Inhibitor of Protein Synthesis , 2002, Science.

[8]  Z. Werb,et al.  Targeted Expression of Stromelysin-1 in Mammary Gland Provides Evidence for a Role of Proteinases in Branching Morphogenesis and the Requirement for an Intact BasementMembrane for Tissue-specific Gene Expression , 2002 .

[9]  Z. Werb,et al.  Shedding light on sheddases: role in growth and development. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[10]  David B. Alexander,et al.  The Membrane-Anchored MMP Inhibitor RECK Is a Key Regulator of Extracellular Matrix Integrity and Angiogenesis , 2001, Cell.

[11]  C. Overall,et al.  Cellular Activation of MMP-2 (Gelatinase A) by MT2-MMP Occurs via a TIMP-2-independent Pathway* , 2001, The Journal of Biological Chemistry.

[12]  P. Poyet,et al.  Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. , 2001, Seminars in oncology.

[13]  C. Overall,et al.  Matrix Metalloproteinase Activity Inactivates the CXC Chemokine Stromal Cell-derived Factor-1* , 2001, The Journal of Biological Chemistry.

[14]  G. Mills,et al.  A Single Nucleotide Polymorphism in the Matrix Metalloproteinase-1 Promoter Enhances Lung Cancer Susceptibility , 2001 .

[15]  R. Hynes,et al.  Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Juan P. Albar,et al.  Membrane Type 1-Matrix Metalloproteinase Is Activated during Migration of Human Endothelial Cells and Modulates Endothelial Motility and Matrix Remodeling* , 2001, The Journal of Biological Chemistry.

[17]  P. E. Van den Steen,et al.  Gelatinase B: a tuner and amplifier of immune functions. , 2001, Trends in immunology.

[18]  R. Flavell,et al.  Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells , 2001, Nature Medicine.

[19]  Allan Balmain,et al.  TGF-β signaling in tumor suppression and cancer progression , 2001, Nature Genetics.

[20]  Mina J. Bissell,et al.  Putting tumours in context , 2001, Nature Reviews Cancer.

[21]  M. Shipp,et al.  Stromelysin‐3 suppresses tumor cell apoptosis in a murine model * , 2001, Journal of cellular biochemistry.

[22]  Jingsong Xu,et al.  Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo , 2001, The Journal of cell biology.

[23]  A. Rosemurgy,et al.  Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  I. Goldberg,et al.  Inhibition of Wilms' tumor growth by intramuscular administration of tissue inhibitor of metalloproteinases-4 plasmid DNA , 2001, Oncogene.

[25]  A. Godzik,et al.  Characterization of matrix metalloproteinase-26, a novel metalloproteinase widely expressed in cancer cells of epithelial origin. , 2001, The Biochemical journal.

[26]  H. Shimada,et al.  Inhibition of peritoneal dissemination in human gastric cancer by MMP-7-specific antisense oligonucleotide. , 2001, Journal of experimental & clinical cancer research : CR.

[27]  H. Mori,et al.  Membrane-Type 1 Matrix Metalloproteinase Cleaves Cd44 and Promotes Cell Migration , 2001, The Journal of cell biology.

[28]  V. V. van Hinsbergh,et al.  Proteolysis of the urokinase-type plasminogen activator receptor by metalloproteinase-12: implication for angiogenesis in fibrin matrices. , 2001, Blood.

[29]  H. Shibuya,et al.  Cloning and characterization of a rat ortholog of MMP-23 (matrix metalloproteinase-23), a unique type of membrane-anchored matrix metalloproteinase and conditioned switching of its expression during the ovarian follicular development. , 2001, Molecular endocrinology.

[30]  J. Quigley,et al.  Growth factor-induced angiogenesis in vivo requires specific cleavage of fibrillar type I collagen. , 2001, Blood.

[31]  Po-Huang Lee,et al.  Aspirin inhibits matrix metalloproteinase-2 activity, increases E-cadherin production, and inhibits in vitro invasion of tumor cells. , 2001, Biochemical and biophysical research communications.

[32]  S. Arii,et al.  Human macrophage metalloelastase gene expression in colorectal carcinoma and its clinicopathologic significance , 2001, Cancer.

[33]  P. Opolon,et al.  AdTIMP-2 inhibits tumor growth, angiogenesis, and metastasis, and prolongs survival in mice. , 2001, Human gene therapy.

[34]  P. Bornstein,et al.  Extracellular Matrix Metalloproteinase 2 Levels Are Regulated by the Low Density Lipoprotein-related Scavenger Receptor and Thrombospondin 2* , 2001, The Journal of Biological Chemistry.

[35]  I. Goldberg,et al.  Stimulation of mammary tumorigenesis by systemic tissue inhibitor of matrix metalloproteinase 4 gene delivery. , 2001, Cancer research.

[36]  C. Sautès-Fridman,et al.  High cancer cell death in syngeneic tumors developed in host mice deficient for the stromelysin-3 matrix metalloproteinase. , 2001, Cancer research.

[37]  T. Mcclanahan,et al.  Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.

[38]  O. Huber,et al.  Cleavage and Shedding of E-cadherin after Induction of Apoptosis* , 2001, The Journal of Biological Chemistry.

[39]  Jeffrey W. Smith,et al.  MT1-MMP Initiates Activation of pro-MMP-2 and Integrin αvβ3 Promotes Maturation of MMP-2 in Breast Carcinoma Cells , 2001 .

[40]  B. Fingleton,et al.  The PEA3 Subfamily of Ets Transcription Factors Synergizes with β-Catenin–LEF-1 To Activate Matrilysin Transcription in Intestinal Tumors , 2001, Molecular and Cellular Biology.

[41]  M. Hidalgo,et al.  Development of matrix metalloproteinase inhibitors in cancer therapy. , 2001, Journal of the National Cancer Institute.

[42]  H. Moon,et al.  Overexpression of membrane-type matrix metalloproteinase-1 gene induces mammary gland abnormalities and adenocarcinoma in transgenic mice. , 2001, Cancer research.

[43]  I. Day,et al.  Invasiveness of cutaneous malignant melanoma is influenced by matrix metalloproteinase 1 gene polymorphism. , 2001, Cancer research.

[44]  A. Mohsenin,et al.  PECAM‐1 shedding during apoptosis generates a membrane‐anchored truncated molecule with unique signaling characteristics , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[45]  D. Boger,et al.  Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[46]  K. Appelt,et al.  Matrix Metalloproteinase Inhibitors for Cancer Therapy , 2000, Cancer Drug Discovery and Development.

[47]  Lars Sottrup-JensenSB,et al.  Human Fibroblast Collagenase-a-Macroglobulin Interactions LOCALIZATION OF CLEAVAGE SITES IN THE BAIT REGIONS OF FIVE MAMMALIAN a-MACROGLOBULINS* , 2001 .

[48]  L. Coussens,et al.  Inflammatory Cells and Cancer: Think Different! , 2001 .

[49]  B. Tang,et al.  ADAMTS: a novel family of extracellular matrix proteases. , 2001, The international journal of biochemistry & cell biology.

[50]  D. Gingras,et al.  Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound. , 2001, Anticancer research.

[51]  Z. Werb,et al.  How matrix metalloproteinases regulate cell behavior. , 2001, Annual review of cell and developmental biology.

[52]  I. Stamenkovic,et al.  Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. , 2001, Cancer research.

[53]  M. Mareel,et al.  Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. , 2001, Journal of cell science.

[54]  B. Sheu,et al.  A novel role of metalloproteinase in cancer-mediated immunosuppression. , 2001, Cancer research.

[55]  U. Felbor,et al.  Generation and degradation of human endostatin proteins by various proteinases , 2000, FEBS letters.

[56]  G. Fuller,et al.  Selective suppression of matrix metalloproteinase-9 in human glioblastoma cells by antisense gene transfer impairs glioblastoma cell invasion. , 2000, Cancer research.

[57]  M. Biondi,et al.  MMP1 and MMP3 polymorphisms in promoter regions and cancer. , 2000, Clinical chemistry.

[58]  S. Bates,et al.  A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[59]  R. Fässler,et al.  Insights into extracellular matrix functions from mutant mouse models. , 2000, Experimental cell research.

[60]  R. Baserga.  The contradictions of the insulin-like growth factor 1 receptor , 2000, Oncogene.

[61]  H. Birkedal‐Hansen,et al.  Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin. , 2000, Cancer research.

[62]  D. Pei,et al.  Cysteine Array Matrix Metalloproteinase (CA-MMP)/MMP-23 Is a Type II Transmembrane Matrix Metalloproteinase Regulated by a Single Cleavage for Both Secretion and Activation* , 2000, The Journal of Biological Chemistry.

[63]  D. Hanahan,et al.  MMP-9 Supplied by Bone Marrow–Derived Cells Contributes to Skin Carcinogenesis , 2000, Cell.

[64]  K. Brand,et al.  Treatment of colorectal liver metastases by adenoviral transfer of tissue inhibitor of metalloproteinases-2 into the liver tissue. , 2000, Cancer research.

[65]  M. Simons,et al.  Thrombospondin Type 1 Repeats Interact with Matrix Metalloproteinase 2 , 2000, The Journal of Biological Chemistry.

[66]  K. W. Kim,et al.  Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. , 2000, Cancer research.

[67]  Shigeyoshi Itohara,et al.  Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.

[68]  Yunbo Shi,et al.  Requirement for Matrix Metalloproteinase Stromelysin-3 in Cell Migration and Apoptosis during Tissue Remodeling in Xenopus laevis , 2000, The Journal of cell biology.

[69]  J. D’Armiento,et al.  Collagenase induction promotes mouse tumorigenesis by two independent pathways , 2000, Molecular carcinogenesis.

[70]  H. Granger,et al.  The heparin binding 25 kDa fragment of thrombospondin‐1 promotes angiogenesis and modulates gelatinase and TIMP‐2 production in endothelial cells , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[71]  P. Soloway,et al.  TIMP-2 Is Required for Efficient Activation of proMMP-2 in Vivo * , 2000, The Journal of Biological Chemistry.

[72]  C. Overall,et al.  Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. , 2000, Science.

[73]  P Delmas,et al.  Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. , 2000, Cancer research.

[74]  M. Mizumoto,et al.  Mouse macrophage metalloelastase gene transfer into a murine melanoma suppresses primary tumor growth by halting angiogenesis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[75]  R. Altman,et al.  Wild Type and Mutant p53 Differentially Regulate the Gene Expression of Human Collagenase-3 (hMMP-13)* , 2000, The Journal of Biological Chemistry.

[76]  R. W. Rauser,et al.  Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[77]  M A Moses,et al.  Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[78]  G. Giannelli,et al.  Role of Cell Surface Metalloprotease Mt1-Mmp in Epithelial Cell Migration over Laminin-5 , 2000, The Journal of cell biology.

[79]  I. Stamenkovic,et al.  Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. , 2000, Genes & development.

[80]  J. Mott,et al.  Post-translational Proteolytic Processing of Procollagen C-terminal Proteinase Enhancer Releases a Metalloproteinase Inhibitor* , 2000, The Journal of Biological Chemistry.

[81]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[82]  C. Benz,et al.  Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents. , 2000, Drugs.

[83]  B. Fingleton,et al.  The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis , 1999, Current Biology.

[84]  A. Albini,et al.  Tumor invasion: molecular shears blunted by green tea , 1999, Nature Medicine.

[85]  E. Scanziani,et al.  BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[86]  L. Matrisian,et al.  Cancer biology: Extracellular proteinases in malignancy , 1999, Current Biology.

[87]  C. Streuli,et al.  Extracellular matrix remodelling and cellular differentiation. , 1999, Current opinion in cell biology.

[88]  Y. Nakamura,et al.  Correlation between expression of the matrix metalloproteinase-1 gene in ovarian cancers and an insertion/deletion polymorphism in its promoter region. , 1999, Cancer research.

[89]  Timo Sorsa,et al.  Tumor targeting with a selective gelatinase inhibitor , 1999, Nature Biotechnology.

[90]  A. Hochberg,et al.  Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[91]  D. Pinkel,et al.  The Stromal Proteinase MMP3/Stromelysin-1 Promotes Mammary Carcinogenesis , 1999, Cell.

[92]  C. López-Otín,et al.  Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinase a overexpressed in brain tumors. , 1999, Cancer research.

[93]  H. Yoshiji,et al.  The Effects of Sustained Elevated Levels of Circulating Tissue Inhibitor of Metalloproteinases‐1 on the Development of Breast Cancer in Mice , 1999, Annals of the New York Academy of Sciences.

[94]  D. Hanahan,et al.  Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. , 1999, Science.

[95]  Y. Sun,et al.  p53 Down-regulates Human Matrix Metalloproteinase-1 (Collagenase-1) Gene Expression* , 1999, The Journal of Biological Chemistry.

[96]  J. Baselga,et al.  Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. , 1999, Cancer research.

[97]  C. Martínez-A,et al.  The Matrix Metalloproteinase-9 Regulates the Insulin-like Growth Factor-triggered Autocrine Response in DU-145 Carcinoma Cells* , 1999, The Journal of Biological Chemistry.

[98]  K. Nabeshima,et al.  Enhanced tumor growth and invasiveness in vivo by a carboxyl-terminal fragment of alpha1-proteinase inhibitor generated by matrix metalloproteinases: a possible modulatory role in natural killer cytotoxicity. , 1999, The American journal of pathology.

[99]  R. Khokha,et al.  Transgenic TIMP-1 inhibits simian virus 40 T antigen-induced hepatocarcinogenesis by impairment of hepatocellular proliferation and tumor angiogenesis. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[100]  M. Schwab,et al.  Membrane-type 1 Matrix Metalloprotease (MT1-MMP) Enables Invasive Migration of Glioma Cells in Central Nervous System White Matter , 1999, The Journal of cell biology.

[101]  T. Kreis,et al.  Guidebook to the extracellular matrix, anchor, and adhesion proteins , 1999 .

[102]  John Calvin Reed.  Mechanisms of apoptosis avoidance in cancer. , 1999, Current opinion in oncology.

[103]  I. Stamenkovic,et al.  Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. , 1999, Genes & development.

[104]  R. Pierce,et al.  Matrix metalloproteinases generate angiostatin: effects on neovascularization. , 1998, Journal of immunology.

[105]  L. Matrisian,et al.  The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis. , 1998, Cancer research.

[106]  L. Matrisian,et al.  Differing effects of endogenous and synthetic inhibitors of metalloproteinases on intestinal tumorigenesis , 1998, International journal of cancer.

[107]  David C. Lee,et al.  An essential role for ectodomain shedding in mammalian development. , 1998, Science.

[108]  S. Weiss,et al.  Matrix Metalloproteinases Regulate Neovascularization by Acting as Pericellular Fibrinolysins , 1998, Cell.

[109]  J. Easton,et al.  Duplication of a genomic region containing the Cdc2L1-2 and MMP21-22 genes on human chromosome 1p36.3 and their linkage to D1Z2. , 1998, Genome research.

[110]  P. Dempsey,et al.  Tyrosine Phosphorylation and Proteolysis , 1998, The Journal of Biological Chemistry.

[111]  W. Yu,et al.  Requirement for Specific Proteases in Cancer Cell Intravasation as Revealed by a Novel Semiquantitative PCR-Based Assay , 1998, Cell.

[112]  R. Cardiff,et al.  CD44v3,8–10 is involved in cytoskeleton‐mediated tumor cell migration and matrix metalloproteinase (MMP‐9) association in metastatic breast cancer cells , 1998 .

[113]  V. Kähäri,et al.  Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. , 1998, Cancer research.

[114]  Y. Itoh,et al.  Comparative analysis of the noncollagenous NC1 domain of type IV collagen: Identification of structural features important for assembly, function, and pathogenesis , 1998, Protein science : a publication of the Protein Society.

[115]  R. Ross,et al.  Cleavage of beta-catenin and plakoglobin and shedding of VE-cadherin during endothelial apoptosis: evidence for a role for caspases and metalloproteinases. , 1998, Molecular biology of the cell.

[116]  J. Fata,et al.  Host TIMP-1 overexpression confers resistance to experimental brain metastasis of a fibrosarcoma cell line , 1998, Oncogene.

[117]  Gabriele Bergers,et al.  MMP-9/Gelatinase B Is a Key Regulator of Growth Plate Angiogenesis and Apoptosis of Hypertrophic Chondrocytes , 1998, Cell.

[118]  J. Foidart,et al.  In Vivo Evidence That the Stromelysin-3 Metalloproteinase Contributes in a Paracrine Manner to Epithelial Cell Malignancy , 1998, The Journal of cell biology.

[119]  S. Itohara,et al.  Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. , 1998, Cancer research.

[120]  D. Gomez,et al.  Mammary carcinoma cells over‐expressing tissue inhibitor of metalloproteinases‐1show vascular endothelial growth factor expression , 1998 .

[121]  D. Gomez,et al.  Mammary carcinoma cells over-expressing tissue inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor expression. , 1998, International journal of cancer.

[122]  R. Cardiff,et al.  CD44v(3,8-10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. , 1998, Journal of cellular physiology.

[123]  Z. Werb,et al.  Matrix Metalloproteinase Stromelysin-1 Triggers a Cascade of Molecular Alterations That Leads to Stable Epithelial-to-Mesenchymal Conversion and a Premalignant Phenotype in Mammary Epithelial Cells , 1997, The Journal of cell biology.

[124]  Z. Werb.  ECM and Cell Surface Proteolysis: Regulating Cellular Ecology , 1997, Cell.

[125]  M. Barbacid,et al.  Identification of Insulin-like Growth Factor-binding Protein-1 as a Potential Physiological Substrate for Human Stromelysin-3* , 1997, The Journal of Biological Chemistry.

[126]  A. Strongin,et al.  Tumor cell invasion through matrigel is regulated by activated matrix metalloproteinase-2. , 1997, Anticancer Research.

[127]  J. Fata,et al.  Altered tumor growth and metastasis of a T-cell lymphoma in Timp-1 transgenic mice. , 1997, Blood.

[128]  W. T. Chen,et al.  Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[129]  G. Giannelli,et al.  Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. , 1997, Science.

[130]  U. Krawinkel,et al.  The matrix metalloproteinase RASI-1 is expressed in synovial blood vessels of a rheumatoid arthritis patient. , 1997, Immunology letters.

[131]  I. Fidler,et al.  Macrophage-Derived Metalloelastase Is Responsible for the Generation of Angiostatin in Lewis Lung Carcinoma , 1997, Cell.

[132]  B. Hogan,et al.  Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[133]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[134]  H. Ohtani,et al.  Stromal Expression of MMP‐9 and Urokinase Receptor Is Inversely Associated with Liver Metastasis and with Infiltrating Growth in Human Colorectal Cancer: A Novel Approach from Immune/Inflammatory Aspect , 1997, Japanese journal of cancer research : Gann.

[135]  Y. Okada,et al.  Expression of membrane-type matrix metalloproteinase 1 (MT1-MMP) in tumor cells enhances pulmonary metastasis in an experimental metastasis assay. , 1996, Cancer research.

[136]  R. Jaenisch,et al.  Targeted mutagenesis of Timp-1 reveals that lung tumor invasion is influenced by Timp-1 genotype of the tumor but not by that of the host. , 1996, Oncogene.

[137]  Z. Werb,et al.  Rescue of mammary epithelial cell apoptosis and entactin degradation by a tissue inhibitor of metalloproteinases-1 transgene , 1996, The Journal of cell biology.

[138]  R. Muschel,et al.  Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. , 1996, Cancer research.

[139]  J. Cossins,et al.  Identification of MMP-18, a putative novel human matrix metalloproteinase. , 1996, Biochemical and biophysical research communications.

[140]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[141]  R. Khokha,et al.  Inhibition of SV40 T antigen-induced hepatocellular carcinoma in TIMP-1 transgenic mice. , 1996, Oncogene.

[142]  Y. Ma,et al.  Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[143]  S. Eccles,et al.  Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). , 1996, Cancer research.

[144]  A. Henney,et al.  Progression of Coronary Atherosclerosis Is Associated with a Common Genetic Variant of the Human Stromelysin-1 Promoter Which Results in Reduced Gene Expression* , 1996, The Journal of Biological Chemistry.

[145]  W. Stetler-Stevenson,et al.  Localization of Matrix Metalloproteinase MMP-2 to the Surface of Invasive Cells by Interaction with Integrin αvβ3 , 1996, Cell.

[146]  John M. Whitelock,et al.  The Degradation of Human Endothelial Cell-derived Perlecan and Release of Bound Basic Fibroblast Growth Factor by Stromelysin, Collagenase, Plasmin, and Heparanases (*) , 1996, The Journal of Biological Chemistry.

[147]  L. Coussens,et al.  Matrix metalloproteinases and the development of cancer. , 1996, Chemistry & biology.

[148]  W. Birchmeier,et al.  Epithelial-mesenchymal transitions in cancer progression. , 1996, Acta anatomica.

[149]  Y. Okada,et al.  Collagenase expression in transgenic mouse skin causes hyperkeratosis and acanthosis and increases susceptibility to tumorigenesis , 1995, Molecular and cellular biology.

[150]  Jack P. Witty,et al.  Decreased tumor formation in 7,12-dimethylbenzanthracene-treated stromelysin-1 transgenic mice is associated with alterations in mammary epithelial cell apoptosis. , 1995, Cancer research.

[151]  A. Strongin,et al.  Mechanism Of Cell Surface Activation Of 72-kDa Type IV Collagenase , 1995, The Journal of Biological Chemistry.

[152]  Lars Holmgren,et al.  Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.

[153]  D. Sheppard,et al.  The alpha v beta 6 integrin promotes proliferation of colon carcinoma cells through a unique region of the beta 6 cytoplasmic domain , 1994, The Journal of cell biology.

[154]  A. Shinagawa,et al.  Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). , 1994, Journal of cell science.

[155]  R. Khokha,et al.  Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. , 1994, Cancer research.

[156]  Z. Werb,et al.  Targeted expression of stromelysin-1 in mammary gland provides evidence for a role of proteinases in branching morphogenesis and the requirement for an intact basement membrane for tissue-specific gene expression [published erratum appears in J Cell Biol 1996 Feb;132(4):following 752] , 1994, The Journal of cell biology.

[157]  M. Thun,et al.  Aspirin use and reduced risk of fatal colon cancer. , 1991, The New England journal of medicine.

[158]  H. Birkedal‐Hansen,et al.  Human fibroblast collagenase-alpha-macroglobulin interactions. Localization of cleavage sites in the bait regions of five mammalian alpha-macroglobulins. , 1989, The Journal of biological chemistry.